Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bayesian adaptive phase II trial of therapies for PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma
ChiCTR2600134832Phase 2Recruiting
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- Jun 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ivonescimab, nimotuzumab, mitoxantrone, irinotecan and tegafur in nasopharyngeal carcinoma (NPC) (4 arms), sponsored by The Fifth Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Objective response rate. Started Jun 2025; status: recruiting.
02
Drugs
ivonescimabnimotuzumabmitoxantroneirinotecantegafur
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2600134832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134832.